Amel Arnaout

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Prevalence of Neuropathic Pain among Patients with Chronic Low-Back Pain in the Arabian Gulf Region Assessed Using the Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale

W El Sissi, Amel Arnaout, M. W. Chaarani et al. · Journal of International Medical Research · 2010 · 55 citations · Full text

Signs Pain Scale, Pain Therapy, Pain Disorders +22

Insights Into the Recognition and Management of SGLT2-Inhibitor-Associated Ketoacidosis: It's Not Just Euglycemic Diabetic Ketoacidosis

Stephanie Dizon, Janine Malcolm, Amel Arnaout · Canadian Journal of Diabetes · 2017 · 42 citations

Metabolic Syndrome, Translational Medicine, Sglt2-inhibitor-associated Ketoacidosis +8

Diabetes Canada Position Statement for People With Types 1 and 2 Diabetes Who Fast During Ramadan

Harpreet S. Bajaj, Tyceer Abouhassan, Muhammad Rauf Ahsan et al. · Canadian Journal of Diabetes · 2018 · 40 citations

Metabolic Syndrome, Diabetes Management, Health Policy +6